Fevicol maker Pidilite delivers double-digit growth, but is 70x earnings justified?
In Q1 FY26, Pidilite’s consolidated revenue rose 10.6 percent year-on-year, EBITDA grew 15.8 percent, and net profit increased by 18.7 percent. While the double-digit growth is impressive, the key question for investors is: can it keep compounding at a pace that justifies 70 times earnings?
In Q1 FY26, Pidilite’s consolidated revenue rose 10.6 percent year-on-year, EBITDA grew 15.8 percent, and net profit increased by 18.7 percent. While the double-digit growth is impressive, the key question for investors is: can it keep compounding at a pace that justifies 70 times earnings?
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
